HN2302 Injection

DRUG2 trials

Sponsors

The Affiliated Hospital of Xuzhou Medical University, Shenzhen MagicRNA Biotechnology Co., Ltd

Conditions

Autoimmune DiseaseRefractory Myasthenia GravisSystemic Lupus ErythematosusSystemic Sclerosis (SSc)

Phase 1

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Not yet recruitingNCT07523282

Shenzhen MagicRNA Biotechnology Co., LtdAutoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)

Start: 2026-12-31End: 2028-06-30Target: 12Updated: 2026-08-12

Unknown Phase

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

RecruitingNCT07413835

The Affiliated Hospital of Xuzhou Medical UniversityRefractory Myasthenia Gravis

Start: 2026-03-17End: 2027-12-01Target: 6Updated: 2026-03-18